Arteris To Provide FlexGen Smart NoC IP In Next-Generation AMD AI Chiplet Designs

In a market reshaped by the compute demands of AI, Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor system IP for accelerating system-on-chip (SoC) creation, today announced AMD (Nasdaq: AMD), a global leader in high-performance and adaptive computing, has licensed FlexGen network-on-chip (NoC) interconnect IP for its next generation of AI chiplet design. FlexGen, Arteris' smart NoC IP technology, will provide high-performance data transport in AMD chiplets powering AI across the company's broad portfolio which spans from data centers to edge and end devices.

The strategic combination and interoperability of Arteris' FlexGen NoC IP with the AMD Infinity Fabric™ interconnect underscores the increasing complexity of modern SoCs and chiplet-based architectures, which now require multiple highly specialized interconnects or NoCs to efficiently meet the demands of modern electronic systems.

"We are excited to collaborate and expand our relationship with AMD, a company recognized globally for its innovation in high performance computing," said K. Charles Janac, president and CEO of Arteris. "With modern chiplets each having between 5 and 20 interconnect networks for data transport, our FlexGen NoC IP will work hand in hand with AMD's Infinity Fabric to accelerate the performance and scalability required by today's most demanding and diverse applications. This latest engagement with AMD exemplifies the transformative impact of Arteris' NoC technology in delivering next-generation silicon solutions for a wide range of markets from the data center to the edge."

"AMD is driving innovations that scale AI from cloud to client by continually developing leadership computing technologies and best-in-class IP," said Mydung Pham, corporate vice president silicon design engineering at AMD. "Integrating Arteris' FlexGen NoC IP technology into a range of AMD chiplets, we can automate interconnect configuration and enable seamless connectivity among SoC components while strengthening the best end-to-end AI compute portfolio in the industry."

Arteris is an industry leader in flexible and configurable network-on-chip IP technology. FlexGen, Arteris' latest NoC IP innovation, is specifically designed to make designing SoCs more efficient and to optimize wire length, reduce latency, and improve power efficiency, addressing the communication and performance needs of increasingly complex multi-die and chiplet-based designs. FlexGen can be utilized as an independent interconnect solution or in combination with proprietary interconnect technology to accelerate design iterations and time to market schedules.

Arteris continues to revolutionize SoC and chiplet performance with innovative technology. FlexGen smart NoC IP leverages AI automation to enhance design productivity through streamlined iteration cycles, and position companies to address the complexities of today's computing systems while dreaming up what comes next. Learn more at arteris.com/FlexGen .

About Arteris

Arteris is a global leader in system IP used in semiconductors to accelerate the creation of high-performance, power-efficient silicon. Arteris network-on-chip (NoC) interconnect IP and system-on-chip (SoC) integration automation software are used by the world's top semiconductor and technology companies to improve overall performance, engineering productivity, reduce risk, lower costs, and bring complex designs to market faster. Learn more at arteris.com .

© 2004-2025 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

Media Contact:
Gina Jacobs
Arteris
+1 408 560 3044
newsroom@arteris.com

This press release was published by a CLEAR® Verified individual.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AMD
The Conversation (0)
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of... Keep Reading...
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors,... Keep Reading...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth... Keep Reading...
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025... Keep Reading...
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety marginDose ranging studies completed InMed Pharmaceuticals Inc. (NASDAQ:... Keep Reading...
Closeup of banknote with overlaid stock market data and charts.

Tech Weekly: Tech Stocks Feel the Heat Amid Valuation Fears

Welcome to the Investing News Network's weekly brief on tech news and tech stocks driving the markets. We also break down next week's catalysts to watch to help you prepare for the week ahead.Don't forget to follow us @INN_Technology for real-time news updates!Securities Disclosure: I, Meagen... Keep Reading...
Westport Reveals CNG Solution for Natural Gas HPDI Engines and North America's Clean Transportation Future

Westport Reveals CNG Solution for Natural Gas HPDI Engines and North America's Clean Transportation Future

Westport Fuel Systems Inc. ("Westport") (TSX:WPRT Nasdaq: WPRT), a supplier of alternative fuel systems and components for the global transportation industry, today announces a breakthrough solution designed to dramatically expand the addressable market for HPDI™ while significantly improving... Keep Reading...
September 2025 Quarterly Activities & Appendix 4C Cashflow

September 2025 Quarterly Activities & Appendix 4C Cashflow

Provaris Energy (PV1:AU) has announced September 2025 Quarterly Activities & Appendix 4C CashflowDownload the PDF here. Keep Reading...
Appendix 4C and Cover Ltr qtr ending 30 Sep 2025

Appendix 4C and Cover Ltr qtr ending 30 Sep 2025

Energy Technologies (EGY:AU) has announced Appendix 4C and Cover Ltr qtr ending 30 Sep 2025Download the PDF here. Keep Reading...
Homerun Resources Inc. Rare Earth Element  Separation Technology Partnership

Homerun Resources Inc. Rare Earth Element Separation Technology Partnership

Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) ("Homerun" or the "Company") is pleased to announce that it has executed a binding Memorandum of Understanding ("MoU") with Magnum Mining & Exploration Limited ("Magnum") (ASX: MGU) (OTCQB: MGUFF), to jointly evaluate the application of... Keep Reading...
Q1 FY26 Quarterly Activities Report & Appendix 4C

Q1 FY26 Quarterly Activities Report & Appendix 4C

Carbonxt Group (CG1:AU) has announced Q1 FY26 Quarterly Activities Report & Appendix 4CDownload the PDF here. Keep Reading...

Latest Press Releases

Related News